TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: GoldenCareTM for the Treatment of Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Female aged 18 years or older~* Subject has clinical bacterial Vaginosis with 4 of 4 positive Amsel's criteria~* Negative pregnancy test~* For 7 day treatment period, subject agrees to refrain from using douches and intravaginal products (i.e. feminine deodorant sprays, spermicides, Nonoxynol-9 products, tampons, and condoms). Subject also agrees to refrain from taking oral or intravaginal antibiotics (unless enrolled in comparator arm),or antifungal agents during the entire study period.~Exclusion Criteria:~* Subject has another infectious or noninfectious cause of vulvovaginitis such asymptomatic candidiasis, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Herpes simplex, human papilloma virus, atrophic vaginitis, lichen sclerosus, or genital warts.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Metronidazole (Type: ACTIVE_COMPARATOR): Oral administration of metronidazole, 500 mg twice daily for 7 consecutive days
- GoldenCare (Type: EXPERIMENTAL): GoldenCare administered intravaginally for at least 6 hours at night for 7 consecutive nights.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Gent for Pharyngeal Gonorrhea (GC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Persons diagnosed with pharyngeal gonorrhea who are not yet treated~Exclusion Criteria:~* Age less than 16 years~* Receipt of antibiotics in ≤30 days~* Known allergy to any aminoglycoside~* History of renal disease (including diagnosis of solitary kidney, chronic renal insufficiency, renal cell carcinoma etc),~* Use of concurrent nephrotoxic drugs or muscle relaxants~* History of diabetes~* History of hearing loss or tinnitus~* Concurrent infection with syphilis or chlamydia~* Pregnancy and/or nursing~* Unable to return for a follow-up visit 4-7 days (+/- 1 day).~* Study team's discretion

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~Male or female patient older than 18 years. Adult patient diagnosed with stage IIIb/IV NSCLC locally advanced or metastatic, with activating mutation(s) of EGFR and who is EGFR-TKI naïve.~Patient for whom a decision of treatment with afatinib monotherapy has been taken in the frame of its marketing authorization.~Out-patient. Patient having given written consent for participation in the study. Patient who is able to participate in the investigator's opinion. Patient affiliated with the French social security.~Exclusion criteria:~Patients participating in an interventional clinical study. Patients for whom a participation in an interventional clinical study is foreseen within 3 months following the study inclusion.~Patients participating in a therapeutic education program.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- group 1 (Type: None): Group without 'remote additional personalised nurse-led follow-up: patients will receive the healthcare given routinely by their medical team
- group 2 (Type: None): Group with 'remote additional personalised nurse-led follow-up: patients will receive telephone calls from a nurse in addition to the healthcare given routinely by their medical team

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Frequency Specific Microcurrent for the Treatment of Diastasis Recti

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
\*\*Patients must be able to get care at Nellis Air Force Base (a military installation) in order to participate in this study\*\*~Inclusion Criteria:~* Active Duty and DoD beneficiary Postpartum Females (12 hours to 24 hours) with Diastasis Rectus Abdominus (DRA) pain~* Aged 18 years or older~* Singleton gestation/delivered (one baby carried and born)~* Vaginal delivery~* Nulliparous (first pregnancy) or multiparous (more than one pregnancy in the past)~Exclusion Criteria:~* less than 18 years of age~* females greater than 24 hours post-partum~* Medical history to include pacemaker~* History of arrhythmia~* Transplant status~* Insulin pump~* Pain pump~* Active cancer~* Inability to measure IRD~* Delivery via caesarean section~* Operative vaginal delivery (vacuum or forceps)~* 3rd or 4th degree vaginal laceration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sham (fake) microcurrent therapy (Type: SHAM_COMPARATOR): Sham (fake) microcurrent therapy (placing the microcurrent pads on the patient and turning the microcurrent box on placebo mode )
- Frequency specific microcurrent therapy (Type: EXPERIMENTAL): Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8),

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nurse PIV Insertion Success With and Without Assistive Devices in Patients 0-12 Months of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to Children's Hospital \& Medical Center Emergency Department, 4th floor medical-surgical unit, or 5th floor medical-surgical/Intermediate Care Unit~* Require non-emergent PIV placement as part of medical plan of care~* Less than or equal to 12 month birth date~Exclusion Criteria:~* Greater than 12 month birth date~* PIV not required~* PIV inserted by practitioner other than RN~* PIV inserted by RN not employed by study areas~* Ward of state~* Require emergent PIV placement~* Primary language is not English or Spanish

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Unassisted vein visualization (Type: ACTIVE_COMPARATOR): The traditional technique of vein visualization and palpation will be used to identify veins during peripheral intravenous line (PIV) insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
- Wee Sight Transilluminator (Type: ACTIVE_COMPARATOR): The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device assists in vein identification by being held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. This will be used to identify veins during peripheral intravenous line (PIV) insertion procedures.
- Near Infra-red light (VeinViewer) (Type: ACTIVE_COMPARATOR): VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein \& surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. This will be used to identify veins during peripheral intravenous line (PIV) insertion procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Tumor classified as stage I-IV located in oropharynx, hypopharynx, larynx (not glottic stage I-II), or oral cavity according to the TNM classification.~* Histopathological diagnosis of invasive squamous cell carcinoma in the primary tumor.~* Informed consent according to the Helsinki declaration and local regula-tions.~* The patient must be candidate for external beam radical radiotherapy, and must be expected to accomplish the treatment.~* Performance status 0-2 according to WHO criteria.~* The patient should not have symptoms of peripheral neuropathy assessed by clinical examination.~* Normal function of liver and kidney by routine laboratory examinations. The patient must not be pregnant~Exclusion Criteria:~* Distant metastases.~* The patient should not be in a state or condition that could be expected to influence the outcome of treatment, or complicate the assessment or the treatment follow-up, or (apart from the present disease) reduce the life expectancy.~* Surgical excision (except biopsy), prior or planned (including elective neck dissection).~* The existence of synchronous multiple malignancies (not leukoplakia).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Accl. RT (Type: ACTIVE_COMPARATOR): Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
- Accl. RT + Nimorazole (Type: EXPERIMENTAL): Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week + Nimorazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate~* Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy~* Detectable metastases~* Any Gleason score~* ECOG performance status 0-2~Exclusion Criteria:~* Prior treatment with chemotherapy~* Prior Immunotherapy~* Prior treatment with gene therapy~* Significant cancer related pain

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: OTHER): Standard of care - chemotherapy
- 1 (Type: EXPERIMENTAL): Immunotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Social security affiliation~* Signed informed consent~* Patients with COVID infection documented by PCR and/or antigenic testing~* Patients belonging to the following groups:~  * asymptomatic patients with PCR-positive PCR~ * patients with mild symptoms and PCR positive~ * seriously symptomatic patients with PCR positive~ * patients in resuscitation with positive PCR~ * Healthy individuals as controls~Exclusion Criteria:~* haemoglobin \< 8g/dL~* Pregnancy, breastfeeding woman~* Patient vaccinated within 15 days prior to inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- asymptomatic patients (Type: None): asymptomatic patients with PCR-positive PCR
- mild symptoms patients (Type: None): patients with mild symptoms and PCR positive
- seriously symptomatic patients (Type: None): seriously symptomatic patients with PCR positive
- patients in resuscitation (Type: None): patients in resuscitation with positive PCR
- heathly volunteer (Type: None): heathly volunteer as control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Erector Spinae Plane Blocks for Rib Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* having a total of 1-6 rib fractures at least 3 cm distal to the costo-transverse joint (bilateral fractures are acceptable, but the total of the two sides combined must not exceed 6 fractures)~* regional anesthetic requested by the admitting service~* patient accepting of a perineural catheter insertion and subsequent study fluid treatment.~Exclusion Criteria:~* chronic opioid use (daily use within the 2 weeks prior to presentation and duration of use \> 4 weeks; of note, any testing for opioid use will not occur as part of the study, but may as standard of care)~* pregnancy~* incarceration~* inability to communicate with the investigators~* weight \< 45 kg or morbid obesity (body mass index \> 40 kg/m2)~* comorbidity precluding either perineural catheter insertion or subsequent ambulatory perineural local anesthetic administration (e.g., current infection at the catheter insertion site, known hepatic or renal insufficiency, immune-compromised status of any etiology)~* any patient unable to correctly perform incentive spirometry as this is the primary outcome measure~* any patient with any degree of decreased mental capacity as determined by the surgical service~* any reason an investigator believes study participation would not be in the best interest of the potential subject~* flail chest~* chest tube~* fracture of the 1st rib on either side~* any injury other than the rib fracture(s) that potentially effects inspiratory effort or volume (e.g., clavicle fracture)~* inability to contact the investigators during the perineural administration, and vice versa (e.g., lack of telephone access).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Treatment (Type: EXPERIMENTAL): This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of ropivacaine 0.3% (continuous block)
- Placebo (Type: PLACEBO_COMPARATOR): This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of QTRAC Technique to Measure Axonal Excitability in Anti-MAG Neuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Anti-MAG neuropathy (peripheral neuropathy and IgM monoclonal gammopathy with anti-MAG activity superior to 1000 BTU)~Exclusion Criteria:~* current treatment with a medication that modifies peripheral nerve excitability (e.g. anticonvulsivants)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Patients (Type: EXPERIMENTAL): Patients suffering from anti-MAG neuropathy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prefrontal Transcranial Random Noise Stimulation in Patients With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* episode of depression (unipolar or bipolar) ( ICD-10)~* female or male between 18 and 70 years old~* skills to participate in all study procedures~* 18 or more points in the Hamilton rating scale or depression~* written informed consent~Exclusion Criteria:~* clinically relevant unstable internal or neurological comorbidity~* evidence of significant brain malformations or neoplasm, head injury~* cerebral vascular events~* neurodegenerative disorders affecting the brain or prior brain surgery~* metal objects in and around body that can not be removed~* pregnancy~* alcohol or drug abuse~* eczema on the head~* heart pacemaker~* high dose tranquillizers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Verum Prefrontal tRNS (Type: EXPERIMENTAL): 2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
- Placebo Prefrontal tRNS (Type: PLACEBO_COMPARATOR): 2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Adenoma Detection Rate in Colonoscopy Performed With EndoRings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients meeting all the below listed criteria are eligible for inclusion in the trial:~1. Age between 50 - 74 years (age range of screening population)~2. Positive HemoCult home test from the Danish Colorectal Cancer Screening Programme~3. Ability to give informed consent to participation in the trial.~Exclusion Criteria:~Patients meeting one or more of the below listed criteria will be excluded from the trial:~1. History of colorectal cancer~2. History of Inflammatory Bowel Disease~3. Part of other control programme (e.g. HNPCC or adenoma control)~4. ASA =/\> 4 and/or necessity of general anaesthesia~5. Former surgery with removal of a part of the colon on either benign or malignant background

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- With EndoRings (Type: ACTIVE_COMPARATOR): Colonoscopy is performed with the use of the cap-device EndoRings II Distal Attachment to be attached to the tip of the colonoscope
- NO EndoRings (Type: NO_INTERVENTION): Colonoscopy is performed conventionally without any caps

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues